Monograph Details
|
|
Neoplasms
> Antimetabolites
|
|
Pentostatin |
| Manufacturer |
|
Bedford Laboratories |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
Antimetabolite. |
| Generic Name |
|
Pentostatin 10mg/vial; lyophilized pwd for IV inj after reconstitution; contains mannitol. |
| Indications |
|
Active hairy cell leukemia. |
| Children |
|
Not recommended. |
| Adults |
|
Ensure adequate hydration. Give as IV bolus or infuse over 20–30 minutes after dilution. 4mg/m2 every other week. Reevaluate after 6 months; discontinue if complete or partial response not achieved; max duration of therapy 12 months. Withhold dose if ANC <200 cells/mm3; may resume when resolved. |
| Precautions |
|
Active infections; treat prior to initiating therapy. Withhold or discontinue therapy if severe rash or neurotoxicity develops. Renal impairment. Monitor and obtain CBCs, liver, and renal function before and during therapy. Pregnancy (Cat. D); avoid use. Nursing mothers: not recommended. |
| Interactions |
|
Concomitant fludarabine: not recommended. Potentiates vidarabine. Acute pulmonary toxicity and hypotension with carmustine, etoposide, and high dose cyclophosphamide (see literature). |
| Adverse Reactions |
|
GI upset, fever, rash, fatigue, leukopenia, pruritus, cough, myalgia, chills, headache, abdominal pain, anorexia, asthenia, stomatitis, rhinitis, dyspnea, anemia, pain, sweating, infections, thrombocytopenia. |
| How Supplied |
|
Single-dose vials—1 |
| Additional Resources |
|
• Related Prescribing Note |
|
|
|
|
